Ikuo Yamamiya
Tsukuba, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example.
Journal: Clinical and translational science
Published: May 22, 2026
A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
Journal: Clinical and translational science
Published: April 15, 2024
A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib.
Journal: Clinical and translational science
Published: May 16, 2023
Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
Journal: Clinical pharmacology in drug development
Published: January 19, 2023
Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: January 18, 2023
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Journal: ACS medicinal chemistry letters
Published: January 12, 2023
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.
Journal: Future oncology (London, England)
Published: August 30, 2022
Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double-Blind, QT/QTc, Phase 1 Study in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: July 27, 2022
Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib.
Journal: Clinical pharmacology in drug development
Published: July 27, 2022
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress.
Journal: Communications biology
Published: March 23, 2021
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Journal: Investigational new drugs
Published: March 08, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Journal: Cancer chemotherapy and pharmacology
Published: January 29, 2021
Last Updated: 09/26/2026